Management of pancreatic cancer in the elderly
Open Access
- 1 January 2016
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 22 (2), 764-775
- https://doi.org/10.3748/wjg.v22.i2.764
Abstract
Currently, pancreatic adenocarcinoma mainly occurs after 60 years of age, and its prognosis remains poor despite modest improvements in recent decades. The aging of the population will result in a rise in the incidence of pancreatic adenocarcinoma within the next years. Thus, the management of pancreatic cancer in the elderly population is gaining increasing relevance. Older cancer patients represent a heterogeneous group with different biological, functional and psychosocial characteristics that can modify the usual management of this disease, including pharmacokinetic and pharmacodynamic changes, polypharmacy, performance status, comorbidities and organ dysfunction. However, the biological age, not the chronological age, of the patient should be the limiting factor in determining the most appropriate treatment for these patients. Unfortunately, despite the increased incidence of this pathology in older patients, there is an underrepresentation of these patients in clinical trials, and the management of older patients is thus determined by extrapolation from the results of studies performed in younger patients. In this review, the special characteristics of the elderly, the multidisciplinary management of localized and advanced ductal adenocarcinoma of the pancreas and the most recent advances in the management of this condition will be discussed, focusing on surgery, chemotherapy, radiation and palliative care.Keywords
This publication has 93 references indexed in Scilit:
- Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPCThe Lancet Oncology, 2012
- Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group TrialJournal of Clinical Oncology, 2011
- The impact of surgical outcome after pancreaticoduodenectomy in elderly patientsWorld Journal of Surgical Oncology, 2011
- Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter StudyJournal of Clinical Oncology, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerThe New England Journal of Medicine, 2011
- Resection Benefits Older Adults with Locoregional Pancreatic Cancer Despite Greater Short‐Term Morbidity and MortalityJournal of the American Geriatrics Society, 2011
- Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2009
- Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO studyAnnals of Oncology, 2008
- Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic reviewBMC Gastroenterology, 2007
- Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapyBritish Journal of Cancer, 2007